A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesTrisomy 21 consistently activates the interferon response.A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.JAK2 inhibitors for myeloproliferative neoplasms: what is next?CMML: Clinical and molecular aspects.Turning the tide in myelodysplastic/myeloproliferative neoplasms.Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.Adult chronic myelomonocytic leukemia with trisomy 11: a case report.Therapy for Chronic Myelomonocytic Leukemia in a New Era.Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines
P2860
Q26752940-11D63D6D-3ED9-4FFA-9342-C1EC537D4573Q37235217-D2D5F51F-3336-462C-BC3D-578A0E23D829Q38602492-5CE76DE8-69FA-44F4-BFAA-AF8166461693Q38644826-1E7BE40A-B81B-4592-A928-6C7E20FFAC8DQ38684435-4612ED98-6B7A-40DB-8811-E36FC6A00420Q38689508-1238B826-84D5-49D8-9A16-4D796C904615Q38712988-C147B642-C007-4F1A-9CD6-EABAE83E83B2Q38747542-C4CE658F-9345-4C62-BBFC-6D18D0448F5DQ38835771-989A5801-6B67-4F70-916C-E70F743EC227Q42335820-167B1ACD-ACC6-4F3B-8697-9851E472760AQ43293633-B31B0E4B-7C30-4155-B18A-32EF49152351Q47132087-AEB52188-7B73-47E5-AADF-3033405A8729Q47853133-857082A7-8311-4145-9A40-C92AA226BAA0Q48205239-B1DD5B83-AE4E-42A6-9165-87137959C040Q48309941-1BA2A890-AC73-46D7-AFB1-38CF96C119ECQ54979651-A8BC72BE-253D-4478-A82C-0D8FFCFE9051Q58125348-FFCBF5BA-8A31-4756-9C7C-2EAC32AC0404
P2860
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A Multi-Institution Phase I Tr ...... Myelomonocytic Leukemia (CMML)
@ast
A Multi-Institution Phase I Tr ...... Myelomonocytic Leukemia (CMML)
@en
type
label
A Multi-Institution Phase I Tr ...... Myelomonocytic Leukemia (CMML)
@ast
A Multi-Institution Phase I Tr ...... Myelomonocytic Leukemia (CMML)
@en
prefLabel
A Multi-Institution Phase I Tr ...... Myelomonocytic Leukemia (CMML)
@ast
A Multi-Institution Phase I Tr ...... Myelomonocytic Leukemia (CMML)
@en
P2093
P2860
P1476
A Multi-Institution Phase I Tr ...... Myelomonocytic Leukemia (CMML)
@en
P2093
Amy Dezern
Cassandra Zimmerman
David P Steensma
Eric Padron
Gail J Roboz
Hanadi Ramadan
Jeffrey E Lancet
Kris Vaddi
Marcio Andrade-Campos
Maria E Balasis
P2860
P304
P356
10.1158/1078-0432.CCR-15-2781
P407
P50
P577
2016-02-08T00:00:00Z